Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene
therapy treatments for human liver diseases have not yielded combined high-level human …

… rAAV vectors were produced using a triple transfection protocol with PEI 25 K. Briefly, the
night before transfection, 293 T cells were seeded onto 15 cm 2 dishes (7.5e6 cells each dish …

While gene transfer using recombinant adeno-associated viral (rAAV) vectors has shown
success in some clinical trials, there remain many tissues that are not well transduced. …

The avermectin analog doramectin (CHC-B1), sold commercially as Dectomax TM , is
biosynthesized by Streptomyces avermitilis. aveC, a gene encoding an unknown mechanistic …

Genetic recombination is a major force driving the evolution of many viruses. Recombination
between two copackaged retroviral genomes may occur at rates as high as 40% per …

Homologous recombination (HR)-based gene therapy using adeno-associated viruses (AAV-HR)
without nucleases has several advantages over classic gene therapy, especially the …

A limitation for recombinant adeno-associated virus (rAAV)-mediated gene transfer into the
central nervous system (CNS) is the low penetration of vectors across the human blood-brain …

Non-random, dynamic three-dimensional organization of the nucleus is important for
regulation of gene expression. Numerous studies using chromosome conformation capture …

Skeletal muscle is ideal for passive vaccine administration as it is easily accessible by
intramuscular injection. Recombinant adeno-associated virus (rAAV) vectors are in consideration …

… linearly ramped from 10000 K to 5000 K. At the same time, the k 2 parameter for constraint
… was linearly ramped down from 5000 K to 10 K. Each simulation was repeated 10 times and …